Syndax Pharmaceuticals (SNDX) Notes Payables (2015 - 2021)
Syndax Pharmaceuticals' (SNDX) quarterly Notes Payables came in at $187000.0 in Q4 2021, up 40.6% quarter-over-quarter from $133000.0 in Q4 2015.
Syndax Pharmaceuticals (SNDX) Notes Payables (2015 - 2021) Analysis & Trends
Syndax Pharmaceuticals' Notes Payables history runs 2 years deep, the most recent figure standing at $187000.0 for Q4 2021.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $187000.0 in Q4 2021; TTM through Dec 2021 was $187000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $187000.0, changed N/A from the prior year.
- Notes Payables climbed to $187000.0 in Q4 2021 per SNDX's latest filing, from $133000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $187000.0 in Q4 2021 and bottomed at $187000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.87 Bn | 1.52 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 187,000.00 |
| Dec 31, 2015 | 133,000.00 |